125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study

Pathogenic variants in BRCA1/2 are an established genetic risk factor for ovarian cancer, with implications for inherited cancer predisposition and treatment selection. In Australia, routine germline BRCA1/2 testing (‘mainstreaming’) was introduced in 2017 for all people diagnosed with non-mucinous high-grade epithelial ovarian, tubal or primary peritoneal cancer. Although this testing is publicly funded on the Medicare Benefits Schedule (MBS), the extent of uptake and equity of access in the population is unclear.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108172
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study

Y.C. Lee, P. A. Cohen, M.L. Friedlander, A. DeFazio et al.
ESMO Open
BRCA gene mutations in cancer
article

125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study

Y.C. Lee, P. A. Cohen, M.L. Friedlander, A. DeFazio, R. Williams, V. Turner, J. Ruiz, B. Daniels, M.A. Merritt, M. Litchfield, N.S. Meagher, P. Webb, S. Pearson, A. Hiyare Hewage
article en

Abstract

Pathogenic variants in BRCA1/2 are an established genetic risk factor for ovarian cancer, with implications for inherited cancer predisposition and treatment selection. In Australia, routine germline BRCA1/2 testing (‘mainstreaming’) was introduced in 2017 for all people diagnosed with non-mucinous high-grade epithelial ovarian, tubal or primary peritoneal cancer. Although this testing is publicly funded on the Medicare Benefits Schedule (MBS), the extent of uptake and equity of access in the population is unclear.

ESMO OpenVol. 11
The University of Sydney (AU), The University of Western Australia (AU), QIMR Berghofer Medical Research Institute (AU), Westmead Hospital (AU), UNSW Sydney (AU), Cancer Australia (AU), Victorian Comprehensive Cancer Centre (AU), Prince of Wales Hospital (AU), Westmead Institute for Medical Research (AU), Australia New Zealand Gynaecological Oncology Group (AU)
Good health and well-being
Openalex Percentile: Top 7%
BRCA gene mutations in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study — Y.C. Lee, P. A. Cohen, et al. · ESMO Open (2026) | TGRS Research Map | TGRS